Literature DB >> 19338493

Impact of pancreatic allograft function on 1-year survival rates after simultaneous pancreatic-renal transplant.

Erika B Rangel1, Claudio S Melaragno, Adriano M Gonzalez, Marcelo M Linhares, Joao R de Sa, Alcides Salzedas, Jose O Medina-Pestana.   

Abstract

OBJECTIVES: Simultaneous pancreatic-renal transplant is an effective treatment for insulin-dependent patients with chronic renal failure. We sought to identify the main influences on pancreatic and patient survival rates after simultaneous pancreas-kidney transplants. PATIENTS AND METHODS: The 1-year patient and pancreas survival rates of 150 patients who had undergone simultaneous pancreas-kidney transplant were analyzed by the Cox proportional hazards regression model and the Kaplan-Meier method. Uni and multivariate analyses were performed in terms of transplant-, recipient-, and donor-related risk factors.
RESULTS: At 1 year, patient and pancreatic allograft survival rates were 82% and 76.7%, respectively. Delayed graft function in the kidney (P = .001, HR 5.41), acute kidney rejection (P = .016, HR 3.36), and intra-abdominal infection (P < .0001, HR 4.15) were the main factors related to 1-year patient survival. Pancreatic allograft survival at 1 year was related to intra-abdominal infection (P < .0001, OR 12.83), vascular thrombosis (P = .002, OR 40.55), acute kidney rejection (P = .027, OR 3.06), donor sodium greater than 155 mEq/L (P = .02, OR 3.27), and dopamine administration exceeding 7.6 microg/kg/min (P = .046, OR 2.85).
CONCLUSIONS: Delayed kidney allograft function and intra-abdominal infection had an important effect on both patient and pancreatic allograft survival rates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19338493

Source DB:  PubMed          Journal:  Exp Clin Transplant        ISSN: 1304-0855            Impact factor:   0.945


  1 in total

1.  Kidney transplant in diabetic patients: modalities, indications and results.

Authors:  Erika B Rangel; João R de Sá; Cláudio S Melaragno; Adriano M Gonzalez; Marcelo M Linhares; Alcides Salzedas; José O Medina-Pestana
Journal:  Diabetol Metab Syndr       Date:  2009-08-26       Impact factor: 3.320

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.